Clinical Trial Update: Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial exploring genetic ablation of CD33 in hematopoietic stem cells to broaden the therapeutic index of CD33-directed immunotherapy. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD33-directed immunotherapy

Snippet

Sponsor: German Cancer Research Center | Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Status: NOT_YET_RECRUITING